Tests tirofiban after clot-busting treatment for acute ischemic stroke
Tests tirofiban, given early after clot-busting treatment, in adults with acute ischemic stroke.
Plain-language title generated from the registry record
Registry title: Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke
Key facts
- Where
- Changchun, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an acute ischemic stroke who got the clot-dissolving drug tenecteplase within 4.5 hours of onset. Tirofiban or placebo must start within 6 hours after that treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Acute ischemic stroke treated with tenecteplase (0.25mg/kg) within 4.5 hours of onset. After that treatment, total NIHSS score of 4 or more, or a single limb motor item score of 2 or more, and total NIHSS of 15 or less. A CT scan of the head after treatment must rule out bleeding in the brain.
- Earlier treatment
- Must have received the standard dose of tenecteplase. Cannot have used antiplatelet, anticoagulant or fibrinolytic drugs within 24 hours before joining. Cannot have had, or be planning, bridge therapy.
Main reasons for not taking part
- Large area of stroke damage (1/3 or more of the middle cerebral artery area)
- Atrial fibrillation or suspected heart clot
- Active bleeding, or bleeding events within 1 year
- Severe kidney or liver problems
- Pregnant or breastfeeding women
Read by machine on 12 November 2026.
Where in China
- The First Hospital of Jilin UniversityChangchun, ChinaContact: Yi Yang, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The First Hospital of Jilin University
- Trial code
- NCT06045156
- Record updated
- 30 December 2025
- Original description
The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVTRead full original descriptionShow less
Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT
Inclusion: Age≥18 years old; Clinically diagnosed as acute ischemic stroke and received standard dose (0.25mg/kg) of tenecteplase IVT within 4.5 hours of onset; Total National Institute of Health stroke scale (NIHSS)≥4 or single limb motor item score≥2, and total NIHSS≤15 after IVT; Tirofiban or placebo treatment can be initiated within 6h after IVT; mRS score before onset≤ 1; Intracranial hemorrhage is ruled out by CT head after IVT.
Exclusion: Received or plan to undergo bridge therapy; Being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial; Atrial fibrillation or suspected cardiac embolism; Accompanied by epileptic seizures; Active bleeding or tendency to bleed after receipt of intravenous thrombolysis; Digestive system bleeding, urinary system bleeding, hemorrhagic retinopathy or other systemic bleeding events within 1 year; Known allergy to tirofiban; Severe renal or liver insufficiency; ALT or AST>3 times of the upper limit of normal value or above; creatinine clearance rate<30 mL/min, creatinine>200μmol/L；; Large area of infarct indicated by radiological imaging(≥1/3 of middle cerebral artery supply area); Using antiplatelet, anticoagulant or fibrinolytic agents within 24h before recruitment; Life expectancy less than 3 months; Pregnant or lactating women; Patients who are unwilling to be followed up or likely to have poor treatment compliance; Other situations that the researcher deems unsuitable for inclusion in the study.